Seroatlas · Human Serome Atlas

SERTAD2

SERTA domain-containing protein 2

Also known as: KIAA0127, Sei-2, SRTD2_HUMAN, TRIP-Br2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q14140
Gene: SERTAD2
Ensembl: ENSG00000179833
Chromosome: 2
Canonical length: 314 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol

OverviewNCBI Gene

Predicted to enable transcription coactivator activity. Acts upstream of or within negative regulation of cell growth. Located in cytosol and nucleoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

314 residues, UniProt reviewed canonical sequence.

>Q14140|SERTAD2
     1  MLGKGGKRKF DEHEDGLEGK IVSPCDGPSK VSYTLQRQTI FNISLMKLYN HRPLTEPSLQ
    61  KTVLINNMLR RIQEELKQEG SLRPMFTPSS QPTTEPSDSY REAPPAFSHL ASPSSHPCDL
   121  GSTTPLEACL TPASLLEDDD DTFCTSQAMQ PTAPTKLSPP ALLPEKDSFS SALDEIEELC
   181  PTSTSTEAAT AATDSVKGTS SEAGTQKLDG PQESRADDSK LMDSLPGNFE ITTSTGFLTD
   241  LTLDDILFAD IDTSMYDFDP CTSSSGTASK MAPVSADDLL KTLAPYSSQP VTPSQPFKMD
   301  LTELDHIMEV LVGS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SERTAD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.61
Highest tissue expression: 81 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 81 nTPM
thymus: 33 nTPM
tonsil: 26 nTPM
esophagus: 21 nTPM
spleen: 18 nTPM
lymph node: 18 nTPM

Single-cell type

esophageal apical cells: 289 nCPM
urothelial cells: 286 nCPM
basal keratinocytes: 195 nCPM
endometrial secretory cells: 195 nCPM
endometrial glandular cells: 192 nCPM
suprabasal keratinocytes: 170 nCPM

Immune cell

plasmacytoid DC: 4.9 nTPM
memory B-cell: 2.5 nTPM
naive B-cell: 2.5 nTPM
eosinophil: 2.3 nTPM
naive CD4 T-cell: 2.2 nTPM
neutrophil: 2 nTPM

Brain region

white matter: 15 nTPM
medulla oblongata: 13 nTPM
midbrain: 12 nTPM
basal ganglia: 12 nTPM
cerebral cortex: 11 nTPM
spinal cord: 11 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SERTAD2.

Disease | ImmuneIEDB

Conditions an epitope on SERTAD2 was assayed in.

narcolepsy B cell
multiple sclerosis B cell
peripheral nervous system disease B cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.43
gnomAD pLI: 0.88
gnomAD missense Z: 0.68
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

negative regulation of cell growth

Molecular functions

transcription coactivator activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SERTAD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SERTAD2 as an antibody target. Whether an autoantibody or antibody against SERTAD2 could matter depends on whether native SERTAD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SERTAD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SERTAD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...